Answers are grounded in this paper and cite their sources.
No AccessJournal of Urology1 Nov 1993The Long-Term Risk of Development of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: Correlation with Stage A1 Disease Wilfred S. Kearse, Thomas M. Seay, and Ian M. Thompson Wilfred S. KearseWilfred S. Kearse More articles by this author , Thomas M. SeayThomas M. Seay More articles by this author , and Ian M. ThompsonIan M. Thompson More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)35884-6AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Although historical data generally attest to a relatively benign course for stage A1 prostate cancer, at least some recent studies suggest that with prolonged followup patients have a significant risk of disease progression. This study was done with the hypothesis that such disease progression is a function of patient age and close, prolonged followup, and not the mere presence of stage A1 disease. A total of 304 patients who underwent transurethral resection of the prostate for histologically confirmed benign prostatic hyperplasia was reviewed, with a minimum followup of 8 years. Of 269 patients with full followup data 187 (70%) are alive without prostate cancer and 61 (23%) died without development of the disease. A total of 21 patients (7.8%) had clinically apparent prostate cancer at a mean of 7.0 years following transurethral resection, of whom 3 (14%) died of prostate cancer and 1 died of other causes. These data suggest that the risk of progression and death from prostate cancer may not be significantly greater in patients with stage A1 disease than in those reported to have benign disease at transurethral prostatectomy. © 1993 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 150Issue 5 Part 2November 1993Page: 1746-1748 Advertisement Copyright & Permissions© 1993 by The American Urological Association Education and Research, Inc.Keywordsprostateprostatic neoplasmsprostatic hypertrophyMetricsAuthor Information Wilfred S. Kearse More articles by this author Thomas M. Seay More articles by this author Ian M. Thompson More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Kearse et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: